# Fusion Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fusion-pharma

- Industry: Biotechnology
- Headquarters: Canada
- Website: www.fusionpharma.com
- Total disclosed funding: $151M
- Latest round: Series B (Apr 1, 2019)
- Investors on record: 12

## About

Based in Ontario, Canada, and founded in 2014 and led by CEO John Valliant, Fusion Pharma operates as a biopharmaceutical that provides radiotherapeutics for the treatment of cancer and other diseases. In March 2024, AstraZeneca agreed to fully acquire Fusion Pharma from Adams Street Partners, Avidity Partners, CPP Investment Board, and more for USD 800 million, or USD 21 per share in cash, including the upfront and maximum potential contingent value payments for approximately USD 2 billion. 

Fusion Pharma developed a product known as FPI-1434, which utilizes the Fast-Clear linker technology to deliver alpha-emitting isotopes to tumors expressing the IGF-1R biomarker. Its approach support that the potent alpha particles cause lethal double-stranded DNA breaks specifically in cancer cells, sparing healthy tissues. The company’s FPI-1434 is currently in Phase 1 clinical trials for solid tumors. In addition, the firm developed FPI-2265, which targets prostate-specific membrane antigen (PSMA) in prostate cancer and is in Phase 2 trials. Fusion Pharma also created FPI-2059, which is a small molecule radio conjugate, targets neurotensin receptor 1 (NTSR1) for treating multiple solid tumors.

## Funding rounds

- Series B, Apr 1, 2019, $105M — Adams Street Partners, OrbiMed Advisors, HealthCap, Seroba, Genesys Capital Management, Johnson & Johnson Innovation, TPG Biotech, Varian Medical Systems, Inc., Rock Springs Capital, Tjänstebilen, Perceptive Advisors, Pivotal Life Sciences
- Series A, Sep 25, 2017, $21M — Adams Street Partners, Seroba, Varian Medical Systems, Inc.
- Series A, Feb 23, 2017, $25M — Genesys Capital Management, Johnson & Johnson Innovation, TPG Biotech, HealthCap, Tjänstebilen

## Investors

- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- HealthCap — Series A, Series B
- Tjänstebilen — Series A, Series B
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A, Series B
- Seroba (https://capitalatlas.ai/funds/seroba) — Series A, Series B
- Varian Medical Systems, Inc. — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Rock Springs Capital — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B